Research · Sep 3, 2026
[ERAS] Erasca Compounds Precision Oncology Franchise Through RAS MAPK Pipeline And Clinical Readouts
Erasca, Inc. is a San Diego, California-headquartered clinical-stage precision oncology biotechnology company that develops the small-molecule precision oncology therapeutics targeting the RAS-MAPK pathway-driven cancers. The business spans the precision oncology therapeutic activity with the pipeline centered around the small-molecule therapeutics targeting the RAS-MAPK pathway including the RAS, the MEK, the ERK, the SHP2, and related RAS-MAPK pathway targets, with the indications spanning the RAS-MAPK pathway-driven cancers including colorectal, lung, pancreatic, and related solid tumor indications, and with the development pipeline supported through in-house clinical development. The revenue and the economics depend on the research and collaboration revenue, the pipeline-advancement progress, the clinical-trial execution, the regulatory progression, the R&D investment, and the operating cost structure. On selected various aggregate disclosure, the fiscal 2025 financial profile reflects total revenue derived from the research and collaboration activity tied to the precision oncology pipeline, an operating profile reflecting a clinical-stage precision oncology company, and a balance-sheet position consistent with a development-stage precision oncology company. The RAS-MAPK pipeline core franchise anchors revenue, supported by the pipeline providing the central pipeline asset of small-molecule therapeutics targeting RAS-MAPK pathway including RAS, MEK, ERK, SHP2, and related RAS-MAPK pathway targets, by the small-molecule precision oncology approach providing the structural differentiation through targeted-mechanism precision, and by the multi-indication pipeline across colorectal, lung, pancreatic, and related RAS-MAPK pathway-driven solid tumor indications providing the multi-indication exposure. The multi-cycle precision oncology pipeline advancement combined with the clinical readouts drives the multi-year trajectory, with the pipeline advancement reflecting the progression driven by clinical-trial enrollment, dose-escalation progression, readout cadence, and related regulatory progression, and the clinical readouts reflecting the multi-year clinical-event environment driven by clinical-trial milestones, efficacy and safety data, and related regulatory-milestone progression. Capital structure reflects the financing of a clinical-stage precision oncology biotechnology company, and a capital allocation framework focused on the R&D investment, the pipeline advancement, the clinical-trial infrastructure, and the balance-sheet management. The bull case anchors on the RAS-MAPK pathway pipeline, the small-molecule precision oncology differentiation, and the targeted oncology market; the bear case anchors on the clinical-trial execution risk, the regulatory environment, and the competitive environment in the precision oncology category.